Abstract 112P
Background
Sarcopenia is known as a prognostic factor before surgery in esophageal carcinoma, however there is limited data about its exact value before neoadjuvant chemoradiotherapy. Therefore, the aim of present study was to evaluate sarcopenia prevalence before neoadjuvant chemoradiotherapy in patients with esophageal cancer and its relation with pathologic response to treatment.
Methods
In this retrospective study, all patients with esophageal cancer referred to Firoozgar hospital, Tehran during 2019 to 2021 who underwent neoadjuvant chemoradiotherapy followed by esophagectomy were included. Muscle mass was measured using a pre-treatment third lumbar vertebra CT-scan slice. Sarcopenia was internationally defined as skeletal muscle index of less than 39 cm2/m2 in women and less than 55 cm2/m2 in men. Association of sarcopenia with demographic and pathologic parameters and patients survival was statistically analyzed.
Results
Totally 67 patients including 34 men (50.7%) entered the study. Squamous cell carcinoma was the most common pathology in 91% of patients. Skeletal muscle index measurement was available in 58 patients in whom 56 (96.6%) showed sarcopenia. The mean of skeletal muscle index in men and women were 19.70 ± 8.01 and 19.63 ± 8.87 cm2/m2 respectively with no statistically significant difference. There was no significant correlation between sarcopenia with age, tumor pathology, tumor site or staging. The mean of skeletal muscle index in T2 tumors was significantly more than other stages (P=0.032). There was no significant relationship between sarcopenia and patients clinical outcome and survival. However skeletal muscle index was significantly higher in patients with complete pathologic response (P=0.004).
Conclusions
Frequency of pre-treatment sarcopenia was very high in patients with esophageal cancer. There was no association between sarcopenia before neoadjuvant chemoradiotherapy and the clinical outcome in patients with esophageal carcinoma but it affected complete pathologic response to therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iran university of medical sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
108P - A meta-analysis of PD-1 inhibitors for the treatment of advanced esophageal squamous cell carcinoma in second-line setting
Presenter: Barinder Singh
Session: Poster viewing 02
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02